Trial Profile
An Exploratory, Open Label Pharmacokinetic - Pharmacodynamic Study to Compare Subcutaneous Versus Intravenous Administration of ACZ885 in Adult Patients With Established Rheumatoid Arthritis.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Canakinumab
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Novartis
- 25 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Feb 2009 Planned end date changed from 1 Dec 2008 to 1 May 2009 as reported by ClinicalTrials.gov.
- 23 Oct 2007 Status changed from initiated to recruiting.